IDENTIFICATION OF POLYMORPHIC HEPATITIS B VIRUSES AND KRAS ONCOGENE MUTATIONS AND CLINICAL USE

摘要

The present application provides a method of monitoring patients of chronic hepatitis B virus (HBV) infection undergoing nucleoside/nucleotide analogue antiviral treatment for treatment efficacy and for risk of drug-resistance, by simultaneous determination of quantities of viral DNA and identification of mutant viruses responsible for drug-resistance. This invention also provides methods and reagents for highly sensitive identification/quantification of KRas oncogene mutations from body fluids or tumor tissues and the use of these methods for cancer risk assessment, cancer early detection, treatment outcome prediction, and treatment monitoring.